Zydus Lifesciences Limited (ZYDUSLIFE)
Outcome of Board Meeting
FY2026 results (audited):
Standalone:
Revenue 114.8bn +5% y-y (109.3bn)
EBITDA 51.4bn -10% y-y (57.3bn)
EBITDA margin 44.8% (52.4%) -760 bps y-y
PAT 35.6bn +6% y-y (33.6bn)
Consolidated:
Revenue 271.5bn +7% y-y (253.0bn)
EBITDA 72.0bn -2% y-y (73.4bn)
EBITDA margin 26.5% (29.0%) -250 bps y-y
PAT 50.9bn +7% y-y (47.7bn)
Dividend: Buyback of equity shares amounting to 11.1bn completed in June 2026
Commentary: Acquisition of Assertio Holdings completed June 16, 2026; impact of torrential rains in July 2026 caused asset damage with insurance claims recognized; one-time impact from new Indian Labour Codes accounted for in FY26.
Source: Original filing PDF
—
view on exchange portal
⚡ You're reading this after the fact — subscribers got it instantly
ISA
Indian Stock Alerts
BOT
🚨 ZYDUSLIFE — Quarterly Results
Revenue: ₹2,35,800 Cr (+12% YoY)
PAT: ₹19,200 Cr (+17% YoY)
EBITDA margin: 16.8%
Board declared ₹10/share dividend. Jio adds 8M subs.
📎 bseindia.com/xml-data/...
🎧 Audio summary ready
✓✓ 6:47 PM
Instant audio summaries2-min AI concall recap delivered with every earnings alert
20-quarter financialsRevenue, PAT, EBITDA, margins — auto-extracted from filings
Forensic red-flag screenAudit, governance, accruals & RPT flags scored automatically
Instant Telegram alertsResults, board meetings, insider trades — within minutes
Add ZYDUSLIFE to your watchlist — all of this, automated.
Sign in with Google14-day Pro trial · No credit card · Cancel anytime
More on Zydus Lifesciences Limited
Important.
The summary above is generated automatically from Zydus Lifesciences Limited's own
public regulatory filing under SEBI LODR. Indian Stock Alerts is
not a SEBI-registered Research Analyst or Investment Adviser.
This page is informational, not investment advice, a recommendation to buy
or sell any security, or any opinion about the company's business, governance
or financial health. Always read the original filing before acting and consult
a registered adviser for investment decisions.